Navigation Links
Telik's Proteasome Inhibitor Program Meets a Preclinical Development Milestone

PALO ALTO, Calif., Aug. 21 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK) announced today that its novel small molecule proteasome inhibitor program met a preclinical development milestone by demonstrating anticancer activity in preclinical models of human leukemia. The proteasome is an important cellular structure necessary for the growth and function of cancer cells and inhibition of the proteasome has been shown to promote cell cycle arrest and cancer cell death or apoptosis. Bortezomib, an approved drug for the treatment of multiple myeloma, is based on this mechanism. Telik's proteasome inhibitors are orally active, non-peptide, non-boron based, and thus may lead to a drug candidate that might have advantages over Bortezomib and other proteasome inhibitors.

"The potentially favorable profile of these compounds was achieved through the use of our TRAP(R) computational drug discovery technology," said James Keck, Ph.D., Vice President of Biology at Telik. "We are currently conducting activities necessary to select a potential development candidate."

Preliminary data on Telik's proteasome inhibitor program was presented at the 2008 annual meeting of the American Association for Cancer Research.

Telik, Inc. of Palo Alto, CA, is a biopharmaceutical company focused on discovering, developing and commercializing novel small molecule drugs to treat serious diseases. The company's most advanced investigational drug candidates in clinical development are TELINTRA(R), a modified glutathione analog for the treatment of cytopenias due to myelodysplastic syndrome or chemotherapy, and TELCYTA(R), a tumor-activated prodrug for the treatment of advanced ovarian cancer and non-small cell lung cancer. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP, which enables the rapid and efficient discovery of small molecule drug candidates. Additional information is available at

This press release contains "forward-looking" statements, including statements regarding the potential qualities and capabilities of drug candidates resulting from the small molecule proteasome inhibitor program described above, including the potential ability of such drug candidates to prevent or stop tumor cell division and starve tumors, and the potential development of any drug candidate to treat cancer. These forward-looking statements are based upon Telik's current expectations. There are important factors that could cause Telik's results to differ materially from those indicated by these forward-looking statements. Detailed information regarding factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release may be found in Telik's periodic filings with the Securities and Exchange Commission, including the factors described in the section entitled "Risk Factors" in its quarterly report on Form 10-Q for the quarter ended June 30, 2008. Telik does not undertake any obligation to update forward-looking statements contained in this press release.

TELIK, the Telik logo, TELINTRA, TELCYTA, and TRAP are trademarks or registered trademarks of Telik, Inc.

SOURCE Telik, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. SuperGens JAK2 Inhibitor, SGI-1252, Inhibits in Vivo Tumor Cell Proliferation
2. SuperGens PIM Kinase Inhibitor, SGI-1776, Causes Tumor Regression in AML Xenograft Models
3. Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma
4. Semafore Pharmaceuticals Reports Positive Interim Results from a Phase I Study of SF1126, a Targeted Pan-PI3K Inhibitor, in Patients with Advanced Solid Tumors
5. Kosans Lead Hsp90 Inhibitor, Tanespimycin, Shows High Level of Activity in Trastuzumab Resistant/Refractory HER2-Positive Breast Cancer in a Phase 2 Trial
6. Clinical Proof of Concept for TGF-beta 2-Inhibitor AP 12009 in Phase Iib EMEA provides Guidance on Phase III Design and Approval Requirements
7. Exelixis Reports Positive Clinical Pharmacodynamics Data for PI3K/mTOR Inhibitor XL765 at ASCO
8. Human Genome Sciences Initiates First Clinical Trial of Lead IAP Inhibitor HGS1029 in Advanced Solid Tumors
9. BiPar Sciences Expands Clinical Development of BSI-201, A Novel PARP Inhibitor, With Phase 2 Trial in Uterine Cancer
10. Ardea Announces Progress with HIV Non-Nucleoside Reverse Transcriptase Inhibitor Program
11. Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment
Post Your Comments:
(Date:11/30/2015)... , Nov. 30, 2015 NHS Supply ... 20 TrueBeam™ machines from Varian Medical Systems (NYSE: ... program to replace older machines and institute modern ... UK,s public hospitals. The order, placed in September, ... licenses for Varian,s RapidArc® and Eclipse™ software systems.    ...
(Date:11/30/2015)... , Nov. 30, 2015  Hanger, Inc. (NYSE: ... restatement of the terms of its previously announced consent ... to its $200,000,000 aggregate principal amount 7⅛% Senior Notes ... (i) the consent fees payable pursuant to the Consent ... Notes and (iii) the expiration date of the Consent ...
(Date:11/30/2015)... , Nov. 30, 2015  Precision Image ... services, is pleased to announce a dramatic expansion ... imaging services. Building on its ISO-9001:2008 certification for ... implemented comprehensive Core Lab protocols and procedures. This ... of research activities.  Their Core Lab services include ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... November 30, 2015 , ... ... Center is one of a select few plastic surgeons in the New York ... removal. , SculpSure™ is the world’s first heat-induced laser treatment for fat loss ...
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... TransPack Volume ... X . Choose from scrolling web-styled transitions to wipes with blur & drop ... direction and more. Seamlessly transition from one clip to the next with TransPack's ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... their strategic partnership at the Radiological Society of North America (RSNA) 2015 ... global providers of cutting-edge dictation and speech-enabled documentation software, announced their partnership ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... In 2016, expected coding changes are likely to include new codes for spine ... not easy to understand the effects of code changes in musculoskeletal, radiology and ...
(Date:11/30/2015)... ... 30, 2015 , ... CTI Group (Holdings) Inc. (OTC:CTIG), a ... communication analytics, announced today that their Proteus® VoIP QMS solution now supports Skype ... Proteus® VoIP QMS (Quality Management System) does this by collecting the ...
Breaking Medicine News(10 mins):